Protein Kinase Inhibitors: all 15,278 studies that test it

Page 64 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLCCompletedNCT00647426Phase 2Results posted
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibTerminatedNCT00644878Phase 2Results posted
• A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated RashCompletedNCT00642473Phase 2Results posted
• Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic CancerTerminatedNCT00640978Phase 2Results posted
• A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaCompletedNCT00639002Phase 2Results posted
• AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyCompletedNCT00638937Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerTerminatedNCT00638378Phase 2Results posted
• Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsCompletedNCT00634920Phase 4Results posted
• CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary CarcinomaCompletedNCT00634751Phase 1/2Results posted
• Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast CancerCompletedNCT00634634Phase 1/2Results posted
• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform NeurofibromasCompletedNCT00634270Phase 2Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerTerminatedNCT00634088Phase 1Results posted
• Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by SurgeryCompletedNCT00633750Phase 2Results posted
• A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT ImagingCompletedNCT00633022Phase 2Results posted
• BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive TreatmentCompletedNCT00632749Phase 2Results posted
• A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast CancerTerminatedNCT00632541Phase 2Results posted
• Study Of Sunitinib In Combination With Folfox In Patients With Colorectal CancerCompletedNCT00631410Phase 1Results posted
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3Results posted
• RAD001 and Bicalutamide for Androgen Independent Prostate CancerCompletedNCT00630344Phase 2Results posted
• RAD001 in Patients With Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00629525Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
• Sorafenib Long Term Extension ProgramCompletedNCT00625378Phase 3Results posted
• Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow BlastsCompletedNCT00624585Not applicableResults posted
• Rapamycin for Prevention of Chronic Graft-Versus-Host DiseaseTerminatedNCT00623012Phase 1/2Results posted
• Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant RecipientsCompletedNCT00622869Phase 3Results posted
• Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast CancerTerminatedNCT00622466Phase 2Results posted
• Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00621686Phase 2Results posted
• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLCCompletedNCT00621049Phase 2Results posted
• The Effects of Sorafenib on Molecular Barrett's Esophagus CancerTerminatedNCT00619242Not applicableResults posted
• Sorafenib Dose Escalation in Renal Cell CarcinomaCompletedNCT00618982Phase 2Results posted
• Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With PsoriasisCompletedNCT00617994Phase 2Results posted
• Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCCompletedNCT00616109Phase 2Results posted
• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)CompletedNCT00615927Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00615199Phase 2Results posted
• A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line RegimenCompletedNCT00615056Phase 2Results posted
• Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung CancerCompletedNCT00613626Phase 2Results posted
• Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic SclerosisCompletedNCT00613171Phase 2Results posted
• Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon CancerCompletedNCT00612586Phase 2Results posted
• To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMDCompletedNCT00612456Phase 2Results posted
• Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.TerminatedNCT00611715Phase 2Results posted
• Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid TumorsCompletedNCT00611468Phase 1Results posted
• AZD0530 Phase II Study in Patients With Advanced Ovarian CancerCompletedNCT00610714Phase 2Results posted
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibCompletedNCT00609804Phase 2Results posted
• Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal CancerTerminatedNCT00609622Phase 2Results posted
• SELINE: Second-Line Iressa Phase IV Study in NSCLC PatientsCompletedNCT00608868Phase 4Results posted
• Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerCompletedNCT00607594Phase 2Results posted
• Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00607113Phase 2Results posted
• A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and GlioblastomaCompletedNCT00606008Phase 2Results posted
• A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.CompletedNCT00605722Phase 2Results posted
• Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine TumorsCompletedNCT00605566Phase 2Results posted
• Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00604721Phase 2Results posted
• Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 StudyCompletedNCT00604383Phase 3Results posted
• A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal CancerCompletedNCT00603915Phase 2Results posted
• Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in JapanCompletedNCT00603512Phase 2Results posted
• Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00602576Phase 2Results posted
• A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.CompletedNCT00600821Phase 2Results posted
• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00600015Phase 2Results posted
• Study Of Sunitinib Plus FOLFOX In Patients With Solid TumorsCompletedNCT00599924Phase 1Results posted
• Phase II Sunitinib Prog Met AIPCCompletedNCT00599313Phase 2Results posted
• Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast CancerTerminatedNCT00597597Phase 2Results posted
• Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + EverolimusCompletedNCT00597506Phase 2Results posted
• Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBMCompletedNCT00597493Phase 2Results posted
• An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant MesotheliomaTerminatedNCT00597116Phase 2Results posted
• A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00596648Phase 1/2Results posted
• Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung CancerTerminatedNCT00592007Phase 2Results posted
• RAD001 Plus Bevacizumab in Metastatic MelanomaCompletedNCT00591734Phase 2Results posted
• Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric CardiaCompletedNCT00591123Phase 2Results posted
• Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant GliomasCompletedNCT00590954Phase 2Results posted
• Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung CancerCompletedNCT00590902Phase 2Results posted
• Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable MeningiomaCompletedNCT00589784Phase 2Results posted
• PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00589550Phase 1Results posted
• Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedNCT00589420Phase 2Results posted
• Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and BevacizumabTerminatedNCT00588900Phase 2Results posted
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
• Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor GeneCompletedNCT00588445Phase 2Results posted
• Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant GliomasCompletedNCT00586508Phase 2Results posted
• Long-term Extension From RCC Phase II (11515)CompletedNCT00586495Phase 2Results posted
• Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)CompletedNCT00586105Phase 3Results posted
• A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00585533Phase 2Results posted
• Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung CancerCompletedNCT00585377Phase 2Results posted
• Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) PatientsTerminatedNCT00585221Phase 2Results posted
• A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerCompletedNCT00585195Phase 1Results posted
• Safety Study of Gleevec® in Children With Pulmonary HypertensionTerminatedNCT00583115Phase 2Results posted
• Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral InfectionTerminatedNCT00582738Phase 2Results posted
• Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)CompletedNCT00577707Phase 2Results posted
• SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaCompletedNCT00577382Phase 2Results posted
• RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT00576680Phase 1/2Results posted
• Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCCTerminatedNCT00576056Phase 2Results posted
• AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00574951Phase 2Results posted
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLCompletedNCT00574873Phase 3Results posted
• Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal AdenocarcinomaCompletedNCT00574171Phase 2Results posted
• Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck CancerTerminatedNCT00573989Phase 1/2Results posted
• Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast CancerTerminatedNCT00573755Phase 2Results posted
• Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor FailureCompletedNCT00570921Phase 2Results posted
• Brain Mets - Capecitabine Plus Sunitinib and WBRTTerminatedNCT00570908Phase 2Results posted
• Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate CancerCompletedNCT00570700Phase 2Results posted
• Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or GefitinibCompletedNCT00570401Phase 2Results posted
• Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal TherapyTerminatedNCT00570258Phase 2Results posted
• UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck CancerCompletedNCT00570232Phase 2Results posted

← Protein Kinase Inhibitors overview